Zhejiang Apeloa Kangyu Pharmaceutical, a controlled subsidiary of Apeloa Pharmaceutical, has received a Drug Registration Certificate from the National Medical Products Administration for pentoxifylline extended-release tablets at 0.4 grams. The drug is registered as a Category 3 chemical drug and is deemed to have passed the generic drug consistency evaluation. It is indicated for peripheral vascular diseases. In 2025, the domestic market size was approximately 52.27 million tablets, with sales of around 262 million yuan. The company stated that the approval will further enrich its product line and enhance market competitiveness.
Apeloa Pharmaceutical Co LtdObtained drug registration certificate for pentoxifylline extended-release tablets, enriching product line and enhancing competitiveness.
As controlled subsidiary, received the drug registration certificate, positively impacting its operations.
